

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Airdoc Technology Co., Ltd.
北京鷹瞳科技發展股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2251)

**(1) ELECTION OF THE NEW SESSION
OF BOARD OF DIRECTORS
AND BOARD OF SUPERVISORS;
(2) PROPOSED AMENDMENTS
TO ARTICLES OF ASSOCIATION;
(3) PROPOSED GRANT OF REPURCHASE MANDATE; AND
(4) CLOSURE OF REGISTER OF MEMBERS**

The Company is pleased to announce that the Board of Directors convened a meeting on November 24, 2023 to consider, and has resolved to approve, among other things, the proposed election of the new session of the Board of Directors, the proposed amendments to the Articles of Association, and the proposed grant of Repurchase Mandate.

On the same date, the Board of Supervisors convened a meeting to consider and has resolved to approve the proposed election of the new session of the Board of Supervisors.

The Board of Directors and the Board of Supervisors have agreed to submit the above proposals to the EGM for consideration and approval.

**(1) ELECTION OF THE NEW SESSION OF THE BOARD OF DIRECTORS AND
THE BOARD OF SUPERVISORS**

The term of office of the first session of the Board of Directors and the first session of the Board of Supervisors will expire in December 2023. In accordance with the relevant laws and regulations and the Articles of Association and the opinions from the nomination committee of the Board of Directors, the list of candidates for the

second session of the Board of Directors and the second session of the Board of Supervisors, which has been respectively considered and approved by the Board of Directors and the Board of Supervisors, is set out below:

I. Election of the New Session of the Board of Directors

On November 24, 2023, the Board of Directors has approved the proposed appointment of each candidate for the second session of the Board of Directors as listed below, subject to the consideration and approval of the Shareholders at the EGM:

Executive Directors	Mr. ZHANG Dalei (張大磊), Ms. WANG Lin (王林), Dr. HE Chao (和超) and Mr. QIN Yong (秦勇)
Independent Non-executive Directors	Mr. NG Kong Ping Albert (吳港平), Dr. WU Yangfeng (武陽豐) and Dr. HUANG Yanlin (黃彥林)

Save for Dr. HE Chao (和超) and Mr. QIN Yong (秦勇), all of the Director candidates are existing Directors. The term of office of the second session of the Board of Directors shall be three years commencing from the date of approval at the EGM. All existing members of the first session of the Board of Directors will continue to perform their roles and responsibilities in accordance with the applicable laws, administrative regulations and the Articles of Association until the election of the new session of the Board of Director is approved at the EGM.

Details of biographies and information of the above Director candidates are set out in Appendix I to this announcement.

Subject to the approval of appointment of each candidate for Directors at the EGM, the Company will enter into service contracts with the Directors. The service contracts set out, among other things, the remuneration package and the length of service of the Directors. Remuneration of the Directors during their terms of office will be implemented based on the remuneration policy of the Company. Subject to the approval at the EGM, the executive Directors holding senior management positions will receive remuneration (paid in the form of cash and/or equity incentives under any share schemes adopted or to be adopted by the Company from time to time) in accordance with the remuneration standards of senior management determined by the Board of Directors and/or their employment contracts signed with the Company. Subject to the approval at the EGM, Mr. NG Kong Ping Albert (吳港平), Dr. WU Yangfeng (武陽豐) and Dr. HUANG Yanlin (黃彥林) as the independent non-executive Directors will receive an annual director's fee of RMB280,000, RMB180,000 and RMB180,000 from the Company, respectively. For details, please refer to the circular of the EGM to be published by the Company in due course.

Details of the membership of committees of the Board of Directors will be reflected in the announcement of the list of Directors of the Company after the EGM.

As of the date of this announcement, save as disclosed in this announcement, none of the Director candidates held any directorship in the last three years prior to the date of this announcement in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas, or served other positions in the Company or any of its subsidiaries. Each Director candidate does not have other relationships with any Directors, Supervisors, senior management, substantial or controlling shareholders of the Company, has not been subject to any penalty or punishment imposed by any relevant authorities or stock exchanges, and does not hold any interest in the shares of the Company or its associated companies within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As of the date of this announcement, save as disclosed in this announcement, in relation to the proposed appointment of Director candidates, there is no other information that needs to be disclosed pursuant to any of the requirements as set out in Rules 13.51(2) of the Listing Rules, nor are there any matters in relation to proposed appointment of Director candidates that need to be brought to the attention of the Shareholders.

Dr. CHEN Yuzhong and Mr. CHEN Hailong will retire by rotation as executive Directors and Mr. CHEN Xin will retire by rotation as a non-executive Director with effect from the conclusion of the EGM. Dr. CHEN Yuzhong and Mr. CHEN Hailong will continue with the Group, shifting their focus towards daily operation management and business development of the Group.

The Board of Directors has not received from the retiring Directors of the first session of the Board of Directors, namely Dr. CHEN Yuzhong, Mr. CHEN Hailong and Mr. CHEN Xin, any disagreement between them and the Board of Directors relating to their retirement, and the Board of Directors is not aware of any matters relating to their retirement that need to be brought to the attention of the Stock Exchange and the Shareholders. The Board of Directors would like to take this opportunity to thank the retiring Directors for their valuable contributions to the Company.

II. Election of the New Session of the Board of Supervisors

On November 24, 2023, the Board of Supervisors has approved the proposed appointment of each candidate for the second session of the Board of Supervisors (excluding the employee representative Supervisor) as listed below, subject to the consideration and approval of the Shareholders at the EGM:

Supervisors Ms. BAI Huihu (白惠惠) and Dr. LUO Ting (羅婷)

Mr. WEI Yubo (魏宇博) was re-elected by the employees of the Company through employees' democratic election procedure as the employee representative Supervisor of the second session of the Board of Supervisors on November 24, 2023, with his appointment taking effect from the conclusion of the EGM.

All of the Supervisor candidates are existing Supervisors. The Second Session of the Board of Supervisors will comprise two non-employee representative Supervisors, subject to the approval of their appointment at the EGM, and the employee representative supervisor, Mr. WEI Yubo, and the term of office of the Second Session of the Board of Supervisors shall be three years commencing from the date of the EGM. All existing members of the first session of the Board of Supervisors will continue to perform their roles and responsibilities in accordance with the applicable laws, administrative regulations and the Articles of Association until the completion of the appointment of the new session of the Board of Supervisors.

Details of biographies and information of Mr. WEI Yubo, Ms. BAI Huihui, Dr. LUO Ting are set out in Appendix II to this announcement.

Subject to the approval of the appointment of each non-employee representative Supervisor candidate as the second session of the Board of Supervisors at the EGM and the effectiveness of the appointment of the employee representative Supervisor, the Company will enter into service contracts with the Supervisors. The service contracts set out, among other things, the remuneration and the length of service of the Supervisors. Remuneration of the Supervisors during their terms of office will be implemented based on the remuneration policy of the Company. Subject to the approval at the EGM, Dr. LUO Ting will receive an annual supervisor's fee of RMB100,000 from the Company, and Mr. WEI Yubo, Ms. BAI Huihui will not receive any supervisor fee from the Company. For details, please refer to the circular of the EGM to be published by the Company in due course.

As of the date of this announcement, save as disclosed in this announcement, none of the Supervisor candidates and the employee representative Supervisor held any directorship in the last three years prior to the date of this announcement in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas, or served other positions in the Company or any of its subsidiaries. Each Supervisor candidate and the employee representative Supervisor does not have other relationships with any Directors, Supervisors, senior management and substantial or controlling shareholders of the Company, has not been subject to any penalty or punishment imposed by any relevant authorities or stock exchanges, and does not hold any interest in the shares of the Company or its associated companies within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As of the date of this announcement, save as disclosed in this announcement, in relation to the proposed appointment of Supervisor candidates and the election of employee representative Supervisor above, there is no other information that needs to be disclosed pursuant to any of the requirements as set out in Rules 13.51(2) of the Listing Rules, nor are there any matters in relation to the proposed appointment of Supervisor candidates and the election of employee representative Supervisor that need to be brought to the attention of the Shareholders.

A circular containing further information of the proposed election of the new session of the Board of Directors and the Board of Supervisors, together with the respective notice of the EGM, will be despatched to the Shareholders in due course.

(2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

On February 17, 2023, the State Council of the PRC and the China Securities Regulatory Commission issued the “Decision of the State Council to Repeal Certain Administrative Regulations and Documents” and the “Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies”, respectively, and related guidelines (collectively, the “**New PRC Regulations**”), which came into effect on March 31, 2023. On the same date as the New PRC Regulations took effect, the “Mandatory Provisions for the Articles of Association of Companies Listed Overseas” and the “Special Regulations on the Overseas Offering and Listing of Shares by Joint Stock Limited Companies” were repealed. The Stock Exchange has made certain consequential amendments to the Listing Rules, which came into effect on August 1, 2023. In light of the above, among other matters, holders of domestic shares and H shares are no longer deemed as different class of Shareholders, and the class meeting requirement applicable to holders of domestic shares and H shares are no longer necessary under the New PRC Regulations.

On November 24, 2023, the Board of Directors resolved to amend the Articles of Association for the purposes of (i) reflecting the updates in the New PRC Regulations and the Listing Rules, and (ii) making other appropriate and housekeeping amendments. The proposed amendments to the Articles of Association are subject to Shareholders' approval by way of special resolution(s) at each of the EGM, the class meeting for holders of H Shares and the class meeting for holders of Domestic Shares.

A circular containing further information of the proposed amendments to the Articles of Association, together with the respective notice of the EGM and relevant class meetings, will be despatched to the Shareholders in due course.

(3) PROPOSED GRANT OF REPURCHASE MANDATE

On November 24, 2023, the Board of Directors resolved to propose the grant of Repurchase Mandate for Shareholders to approve at the EGM.

Subject to the Shareholders' approval of the Repurchase Mandate at the EGM and relevant class meetings and in accordance with the terms therein, the Company would be allowed to repurchase up to a maximum of 5,341,700 H Shares, representing 10% of the aggregate nominal amount of the issued H Shares as of the date of passing the resolution approving the Repurchase Mandate, assuming that no further Shares will be issued by the Company since the date of this announcement and up to the date of the EGM.

The Repurchase Mandate shall be in force from the date of the passing of the relevant resolution at the EGM until the earliest of: (a) the conclusion of the next annual general meeting of the Company; (b) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of Association or by any applicable laws to be held; and (c) the date on which the authority given under the special resolution approving the Repurchase Mandate is revoked or varied by an special resolution of the Shareholders.

Under the Listing Rules, the Company is required to give to the Shareholders all information which is reasonably necessary to enable the Shareholders to make an informed decision as to whether to vote for or against the resolution to grant the Repurchase Mandate. An explanatory statement required by the Listing Rules will be included in the circular to be despatched to the Shareholders in due course.

The Directors believe that the Repurchase Mandate is in the interests of the Company and the Shareholders as a whole. An exercise of the Repurchase Mandate may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the Company's net assets per Share and will only be made when the Directors believe that a repurchase will benefit the Company and the Shareholders as a whole.

(4) CLOSURE OF REGISTER OF MEMBERS

The Board of Directors hereby announces that the Company will hold (i) the EGM at 10:30 a.m. on Friday, December 29, 2023, (ii) the 2023 first class meeting for holders of Domestic Shares immediately after the conclusion of or any adjourned meeting of the EGM, and (iii) the 2023 first class meeting for holders of H Shares immediately after the conclusion of or any adjourned meeting of the EGM and the 2023 first class meeting for holders of Domestic Shares at Room 21, 4th Floor, Building 2, A2 Yard, West Third Ring North Road, Haidian District, Beijing, PRC.

For the purpose of determining the list of holders of H Shares who are entitled to attend the EGM and the 2023 first class meeting for holders of H Shares, the register of members of H Shares will be closed from December 9, 2023 to December 29, 2023 (both days inclusive), during which period no transfer of H Shares will be registered. In order to be entitled to attend and vote at the EGM and the 2023 first class meeting for holders of H Shares, unregistered holders of H Shares shall ensure all transfer documents accompanied by the relevant share certificates are lodged with the Company's H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not later than 4:30 p.m. on December 8, 2023 for registration.

A circular and the respective notices of the EGM and relevant class meetings as well as the related proxy form will be dispatched to the Shareholders in due course.

DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context requires otherwise:

“Articles of Association”	the articles of association of the Company, as amended from time to time
“Board of Directors”	the board of Directors
“Board of Supervisors”	the board of Supervisors
“Company”	Beijing Airdoc Technology Co., Ltd. (北京鷹瞳科技發展股份有限公司), a joint stock company incorporated in the PRC with limited liability on September 9, 2015 and the H Shares of which were listed on the Stock Exchange on November 5, 2021
“Director(s)”	the director(s) of the Company
“Domestic Share(s)”	ordinary shares in the share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for and paid up in RMB by domestic investor

“EGM”	the 2023 second extraordinary general meeting of the Company to be held at 10:30 a.m. on Friday, December 29, 2023 at Room 21, 4th Floor, Building 2, A2 Yard, West Third Ring North Road, Haidian District, Beijing, PRC
“Group”, “we” or “us”	the Company and its subsidiaries
“H Share(s)”	overseas listed foreign share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which is(are) subscribed for and traded in Hong Kong dollars and listed on the Stock Exchange
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“PRC”	the People’s Republic of China, but for the purpose of this announcement and for geographical reference only and except where the context requires, references in this announcement to China and the PRC do not include Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“Repurchase Mandate”	the repurchase mandate proposed to be granted to the Directors at the EGM to exercise the powers of the Company to repurchase up to a maximum of 10% of the issued share capital of the Company as of the date of passing of the relevant resolution granting such mandate at the EGM
“RMB”	Renminbi Yuan, the lawful currency of China
“Share(s)”	shares in the share capital of our Company, with a nominal value of RMB1.00 each, comprising Domestic Shares and H Shares
“Shareholder(s)”	holder(s) of the Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

“Supervisor(s)” the supervisor(s) of our Company

“%” percent

By order of the Board
Beijing Airdoc Technology Co., Ltd.
Mr. ZHANG Dalei
Chairman of the Board

Hong Kong, November 24, 2023

As of the date of this announcement, the Board comprises Mr. ZHANG Dalei, Dr. CHEN Yuzhong, Mr. CHEN Hailong and Ms. WANG Lin as executive Directors; Mr. CHEN Xin as a non-executive Director; and Mr. NG Kong Ping Albert, Dr. WU Yangfeng and Dr. HUANG Yanlin as independent non-executive Directors.

APPENDIX I

Details of Biographies and Information of Candidates for Directors

Mr. ZHANG Dalei (張大磊), aged 40, our founder, joined our Group on September 9, 2015 and was appointed as a Director and chairman of the Board of Directors on the same date. Mr. Zhang was re-designated as an executive Director on April 30, 2021. Mr. Zhang is primarily responsible for the overall management of the business strategy and corporate development of our Group. Furthermore, Mr. Zhang serves as a director in certain subsidiaries of the Company.

Mr. Zhang has accumulated over 13 years of robust experience in the management of high-tech companies and accumulated technological knowledge in the R&D of AI technologies. From April 2015 to September 2015, Mr. Zhang served as the product vice president of Sina Technology (China) Company Limited (新浪網技術(中國)有限公司). From June 2014 to April 2015, Mr. Zhang served as a vice president at Synapse Computer System (Shanghai) Co., Ltd. (突觸計算機系統(上海)有限公司), a wholly-owned subsidiary of PPLive Corporation, where he was mainly responsible for product development and technology. From May 2010 to May 2013 Mr. Zhang served as the chief technology officer of Ethos Technologies Inc. (宇思信德科技(北京)有限公司). From March 2008 to April 2010, Mr. Zhang served as a program manager of Macintosh Business Unit of Microsoft (China) Co., Ltd. (微軟(中國)有限公司).

Mr. Zhang received his bachelor's degree in pharmaceuticals in the PRC in June 2003. Mr. Zhang was granted the "Certified Standards Professional" and recognized as the "Most Valuable Professional" by Microsoft in April 2008 and April 2011, respectively. Mr. Zhang was certified as the Information System Project Manager (Senior) (信息系統項目管理師(高級)) by Beijing Human Resources and Social Security Bureau (北京市人力資源社會保障局) in November 2010. Mr. Zhang has been serving as a member of Professional Committee of Smart Medical of Chinese Association for Artificial Intelligence (中國人工智能學會智慧醫療專業委員會) since December 2020. Mr. Zhang was appointed as the vice chairman of industry development and coordination committee by the Asia Optometric Management Academy for a two-year term starting from March 2023.

As of the date of this announcement, Mr. Zhang has direct interest in 12,074,198 Domestic Shares and 5,174,656 H Shares, is interested in 3,107,040 H Shares grant yet unvested under the 2022 equity incentive scheme of the Company, and is deemed to be interested in (i) 2,335,363 Domestic Shares and 2,995,945 H Shares held by Beijing Airdoc Universe Technology Center L.P. (北京鬱金香宇宙科技中心(有限合夥)), where Mr. Zhang serves as the general partner, and (ii) 1,398,058 Domestic Shares and 1,101,459 H Shares held by his concert parties, Mr. GAO Fei and Mr. CHEN Mingqiang.

Ms. WANG Lin (王林), aged 39, joined our Group as the general counsel in September 2017. On March 30, 2023, Ms. Wang was appointed as an executive Director. Ms. Wang serves as a director or a supervisor in certain subsidiaries of the Company.

Ms. Wang has approximately 12 years of experience in legal practice. Prior to joining the Group, from March 2011 to July 2017, Ms. Wang served as a legal counsel in Beijing Sohu New Media Information Technology Co., Ltd. (北京搜狐新媒體信息技術有限公司), a wholly-owned subsidiary of Sohu.com Limited (formerly known as Sohu.com Inc.), whose shares are listed on NASDAQ (ticker symbol: SOHU).

Ms. Wang obtained a bachelor's degree in laws from Hubei University (湖北大學) in June 2007 and a master's degree in laws from Beijing Technology and Business University (北京工商大學) in July 2010.

Dr. HE Chao (和超), aged 50, was appointed as our chief technology officer on October 23, 2018. He has led the development of our research and development team, which laid the foundation for the development of our Airdoc-AIFUNDUS, since 2018.

Dr. He possesses more than 20 years of experience in research and development, and is the inventor of more than 50 Chinese patents or patent applications and 30 international patents in core technologies in the fields of artificial intelligence, intelligent hardware, and medical devices. Dr. He worked for Microsoft (China) Co., Ltd. from June 2009 to March 2015, where his last position was the principal software engineering manager. From February 2015 to October 2018, Dr. He served as the R&D vice president of Shanghai Xiaoyi Technology Co., Ltd. (上海小蟻科技有限公司).

Dr. He received his bachelor's degree in radio technology and information system from Tsinghua University (清華大學) in the PRC in July 1995 and his doctor of philosophy in electrical engineering from the Ohio State University in the U.S. in 2005.

Mr. QIN Yong (秦勇), aged 43, joined our Group as the product operations manager in September 2017 and is mainly responsible for the operation of the Company's products. Since August 2022, Mr. Qin has served as the chief operating officer of Beijing Airdoc Intelligent Technology Co. Ltd. (北京鷹瞳智能科技有限公司), a subsidiary of the Group. Since November 2021, Mr. Qin has served as a director of Beijing Airdoc Medical Technology Co., Ltd. (北京鷹瞳醫療科技有限公司), a subsidiary of the Group.

From September 2010 to June 2016, Mr. Qin worked for China Mobile Design Institute (中國移動設計院), where he successively served as a project manager responsible for supporting the construction and operation aspects of the Mobile 10086 Portal, and then as the product leader of the mobile points mall responsible for the development of the mobile points mall portal. From August 2006 to September 2009, Mr. Qin served as a technical support manager at Microsoft (China) Co., Ltd. (微軟(中國)有限公司), where he was mainly responsible for the promotion of Microsoft's development technology.

Mr. Qin obtained his bachelor's degree in computer science and technology from Yanshan University (燕山大學) in the PRC in July 2002 and his master's degree in Geographic Information System from China University of Geosciences (中國地質大學) in 2006.

Mr. NG Kong Ping Albert (吳港平), aged 66, joined our Group and was appointed as an independent non-executive Director on April 30, 2021. Mr. Ng is primarily responsible for addressing conflicts and giving strategic advice and guidance to the business and operations of our Group.

Mr. Ng was the chairman of Ernst & Young China, the managing partner of Ernst & Young in Greater China and a member of Ernst & Young's Global Executive Committee before retirement. He has over 30 years of professional experience in accounting in Hong Kong and Mainland China. Prior to joining Ernst & Young, Mr. Ng served as Managing Partner of Arthur Andersen in Greater China, Managing Partner, China Operation of PricewaterhouseCoopers and the managing director of Citigroup China Investment Banking.

Mr. Ng is an independent non-executive Director of Ping An Insurance (Group) Company of China, Ltd. (a company listed on the Shanghai Stock Exchange (stock code: 601318) and the Stock Exchange (stock code: 02318)), China International Capital Corporation Limited (a company listed on the Shanghai Stock Exchange (stock code: 601995) and the Stock Exchange (stock code: 03908)), an independent director of Alibaba Group Holding Limited (a company listed on the New York Stock Exchange (stock code: BABA) and the Stock Exchange (stock code: 09988)), and an independent non-executive director of Shui On Land Limited (a company listed on the Stock Exchange (stock code: 272)).

Mr. Ng is the president of the second session of Hong Kong China Chamber of Commerce and once served as a member of the first and second Consulting Committee of Corporate Accounting Standard (企業會計準則諮詢委員會), an advisor of the Hong Kong Business Accountants Association and a member of the Advisory Board of the School of Accountancy of The Chinese University of Hong Kong. Mr. Ng is also a member of the audit committee of The Chinese University of Hong Kong (Shenzhen) and a council member of the Education Foundation of The Chinese University of Hong Kong (Shenzhen).

Mr. Ng has obtained his bachelor's and master's degree in business administration from The Chinese University of Hong Kong in December 1981 and October 1988, respectively. Mr. Ng is also a member of Hong Kong Institute of Certified Public Accountants (HKICPA), Chartered Accountants Australia and New Zealand (CAANZ), CPA Australia (CPAA) and Association of Chartered Certified Accountants (ACCA).

Dr. WU Yangfeng (武陽豐), aged 61, was appointed as an independent Director on December 25, 2020. Dr. Wu was re-designated as an independent non-executive Director on April 30, 2021. Dr. Wu is primarily responsible for addressing conflicts and giving strategic advice and guidance to the business and operations of our Group.

Since July 2006, Dr. Wu has been working at medicine department of Peking University (北京大學) with his current position being the executive deputy director of clinical research institute, a professor of clinical research methodology and a doctoral supervisor.

Before July 2006, Dr. Wu worked at Fuwai Hospital (阜外醫院) with his last position as a director of epidemiology research office, a researcher and a doctoral supervisor. Dr. Wu received his bachelor's degree of medicine from Shanxi Medical College (山西醫學院) in the PRC in December 1984. Dr. Wu received his master's degree and doctor's degree in medicine from Peking Union Medical College (中國協和醫科大學) in the PRC in December 1987 and July 1996, respectively.

Dr. HUANG Yanlin (黃彥林), aged 50, joined our Group on December 25, 2020 and was appointed as an independent Director on the same date. Dr. Huang was re-designated as an independent non-executive Director on April 30, 2021. Dr. Huang is primarily responsible for addressing conflicts and giving strategic advice and guidance to the business and operations of our Group.

Dr. Huang has been serving as an industry advisor in KKR Asia Limited since October 2022. From July 2020 to April 2021, Dr. Huang served as the chief technology officer of 9F Inc. (玖富集團), a company whose shares are listed on NASDAQ (ticker symbol: JFU), where he was primarily responsible for overseeing R&D. From August 2019 to July 2020, Dr. Huang served as the chief technology officer of GOME Holdings Group (國美控股集團), where he was primarily responsible for leading R&D. From September 2016 to June 2019, Dr. Huang served as the chief technology officer of Vipshop Holdings Limited, a company whose shares are listed on the New York Stock Exchange (ticker symbol: VIPS), where he was primarily responsible for leading R&D. From April 2015 to September 2016, Dr. Huang served as the chief technology officer of Sina Technology (China) Company, where he was primarily responsible for leading R&D. Dr. Huang previously served as the chief technology officer of Shanghai SynaCast Media Tech Co., Ltd. (上海聚力傳媒技術有限公司) (PPTV), where he was primarily responsible for leading R&D. Dr. Huang once worked at Microsoft.

Dr. Huang received his bachelor's degree of science in microbiology from Wuhan University (武漢大學) in the PRC in July 1993. Dr. Huang received his doctor's degree in biochemistry from State University of New York at Buffalo in the United States in September 1999. Dr. Huang received his master's degree in computer science from the University of Virginia in the United States in January 2001.

APPENDIX II

Details of Biographies and Information of Supervisor Candidates and Employee Representative Supervisor

Mr. WEI Yubo (魏宇博), aged 41, joined our Group on April 30, 2016 and was appointed as a Supervisor on December 7, 2016. Mr. Wei is the chairman of the Board of Supervisors and primarily responsible for overseeing our business operations. Mr. Wei serves as a supervisor in certain subsidiaries of the Company.

From July 2012 to April 2016, Mr. Wei served as an engineer of IGT Technology (Beijing) Co., Ltd. (IGT科技開發(北京)有限公司), where he was primarily responsible for software development and testing. From April 2006 to June 2012, Mr. Wei worked successively at Beyondsoft Technology Co., Ltd. (博彥科技股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 002649) and Microsoft, where he was mainly responsible for Mac Office Testing.

Mr. Wei received his bachelor's degree in electronic information engineering from Jilin University (吉林大學) in the PRC in July 2004.

Ms. BAI Huihui (白惠惠), aged 33, joined our Group on December 25, 2020 and was appointed as a Supervisor on the same date. Ms. Bai is primarily responsible for overseeing our business operations.

Ms. Bai holds the following positions outside our Group concurrently. Since April 2020, Ms. Bai has been serving as the chairman of the board and general manager at Guoke Kaiyan Capital Co., Ltd. (國科開研資本有限公司) (“**Guoke Capital**”). Since March 2019, Ms. Bai has been serving as an executive director and general manager at Geluoli Asset Management Co., Ltd. (格羅力資產管理有限公司). Since April 2020, she has been serving as a supervisor at Beijing Kaiyan Investment Management Co., Ltd. (北京開研投資管理有限公司).

From March 2019 to June 2019, Ms. Bai served as a supervisor at Guoke Capital. From June 2019 to April 2020, she served as a director at Guoke Capital.

Ms. Bai received her bachelor's degree in light information science and technology from Shenzhen University (深圳大學) in the PRC in June 2012.

Dr. LUO Ting (羅婷), aged 48, joined our Group on May 19, 2022 and was appointed as a Supervisor on the same date, Dr. Luo is primarily responsible for overseeing our business operations.

Dr. Luo is currently serving as a tenured associate professor at School of Economics and Management, Tsinghua University, and an independent director of (i) Digital China Information Service Group Company Ltd. (神州數碼信息服務集團股份有限公司), a company whose shares are listed on the Shenzhen Stock Exchange (stock code: 000555); and (ii) Beijing Sanyuan Foods Co., Ltd. (北京三元食品股份有限公司), a company whose shares are listed on the Shanghai Stock Exchange (stock code: 600429). Dr. Luo served as an independent director of (i) Beijing Thunisoft Co., Ltd. (北京華宇軟件股份有限公司), a company whose shares are listed on the Shenzhen Stock Exchange (stock code: 300271) from March 2020 to August 2022; and (ii) IAT Automobile Technology Co., Ltd. (阿爾特汽車技術股份有限公司), a company whose shares are listed on the Shenzhen Stock Exchange (stock code: 300825) from July 2018 to April 2022.

Dr. Luo participated in research projects covering topics of accounting and finance.

Dr. Luo has been qualified as a Certified Public Accountant of the PRC. Dr. Luo obtained a bachelor's degree in business management from Peking University and a doctor of philosophy in accounting from University of Wisconsin-Madison in the United States in 1997 and 2007, respectively.